Amrize Ltd (AMRZ) Gets Overweight Nod and $62 Price Target from Morgan Stanley

Morgan Stanley kicked off coverage of Amrize Ltd (OTCBB: AMRZ) with an Overweight rating and a $62.00 price target, spotlighting its aggressive bolt-on acquisition strategy and robust free cash flow outlook.

Key Investment Highlights

• 13% Revenue CAGR & 16% EBITDA CAGR since 2021, driven by 17 strategic acquisitions.

• $7.5 billion projected cumulative free cash flow (2025–2028), underpinning future bolt-ons.

• Current <1x Net Debt/EBITDA, offering ample financial flexibility.

Analyze Amrize’s historical growth in revenue, EBITDA, and free cash flow via the Financial Growth Statement Analysis API.

Market Position & Upside Risks

• 5th largest U.S. aggregates player; 3% residential roofing share.

• Morgan Stanley’s base case assumes 2% annual bolt-on growth.

• “Clear upside risk” if larger platform acquisitions accelerate scale.

Monitor Amrize’s leverage and profitability trends—like Net Debt/EBITDA and EBITDA margin—using the Ratios TTM Statement Analysis API.

Strategic Takeaway
With a sub-1x leverage profile and strong free cash generation, Amrize is well-positioned to fund further acquisitions and drive EBITDA growth toward Morgan Stanley’s projected 15% CAGR (2025–2030) under a 1.5x leverage scenario—outpacing peers and justifying the Overweight stance.

Investors can leverage these FMP APIs to track Amrize’s evolving growth metrics and capital structure in real time, ensuring alignment with Morgan Stanley’s bullish thesis.